REFERENCES
- Hall W, Darke S. Trends in opiate overdose deaths in Australia 1979–1995. Drug Alcohol Depend 1998; 52: 71–77
- Smyth B, Fan J, Hser Y I. Life expectancy and productivity loss among narcotics addicts thirty-three years after index treatment. J Addict Dis 2006; 25: 37–47
- Mark T L, Woody G E, Juday T, Kleber H D. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001; 61: 195–206
- Gowing L R, Farrell M, Ali R L, White J M. Alpha2 adrenergic agonists in opioid withdrawal. Addiction 2002; 97: 49–58
- McCambridge J, Gossop M, Beswick T, Best D, Bearn J, Rees S, Strang J. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: Comparison of lofexidine +naloxone, lofexidine + placebo, and methadone. Drug Alcohol Depend 2007; 88: 91–95
- Glasper A, Gossop M, de Wet C, Reed L, Bearn J. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification. Pharmacology 2008; 81: 92–96
- Bearn J, Gossop M, Strang J. Randomized double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend 1996; 43: 87–91
- Carnwath T, Hardman J. Randomized double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend 1998; 50: 251–254
- Gold M S, Pottash A C, Sweeney D R, Extein I, Annitto W J. Lofexidine blocks acute opiate withdrawal. NIDA Research Monograph 1982; 41: 264–268
- Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, Montoya I, Fischman M W, Collins J, McSherry F, Boardman K, Davies D K, O'Brien C P, Ling W, Kleber H, Herman B H. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend 2008; 97: 158–168
- Midgley I, Chasseaud L F, Taylor T, Darragh A. The absorption and excretion of 14C-lofexidine hydrochloride in man. Arzneimittelforschung 1982; 32: 972–975
- Midgley I, Fowkes A G, Chasseaud L F, Hawkins D R, Girkin R, Kesselring K. Biotransformation of lofexidine in humans. Xenobiotica 1983; 13: 87–95
- Al Ghananeem A M. Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. J Pharm Sci 2008; 98: 319–326
- Yu E, Miotto K, Akerele E, O'Brien C P, Ling W, Kleber H, Fischman M W, Elkashef A, Herman B H, Al Ghananeem A M. Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. The American Journal of Drug and Alcohol Abuse 2008; 34: 606–611
- Davies D S, Wing A M, Reid J L, Neill D M, Tippett P, Dollery C T. Pharmacokinetics and concentration-effect relationships of intravenous and oral clonidine. Clin Pharmacol Ther 1977; 21: 593–601
- MacGregor T R, Relihan G L, Keirns J J. Pharmacokinetics of oral sustained release clonidine in humans. Arzneimittelforschung 1985; 35: 440–446
- Ingelman-Sundberg M, Sim S C, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496–526